Medically reviewed by Stella Bard, MD Psoriatic arthritis (PsA) is a chronic (long-term) condition that includes symptoms of ...

Discover the signs of psoriatic arthritis, from joint pain and skin changes to nail damage and fatigue, plus the latest treatment options for this condition.

Visible signs of psoriatic arthritis appear months and even years before a person develops the full-blown inflammatory joint ...

But experts say T2T can be more complex for people with psoriatic arthritis (PsA). In treat-to-target, medications are adjusted over time to reach a predetermined treatment goal. The ultimate aim is ...

Oral medication apremilast (Otezla) was approved in 2014 for clinically active psoriatic arthritis. Apremilast selectively blocks phosphodiesterase 4 (PDE4), an enzyme involved in inflammation. In one ...

Secukinumab, a fully human monoclonal antibody that directly inhibits IL-17A, has provided significant and sustained improvement in the signs and symptoms of active PsA and axSpA.16–18 The objective ...

Researchers have established that uveitis (a severe inflammatory eye disease) is bidirectionally linked to psoriatic arthritis but not with arthritis-free psoriasis. The study was published in the ...

Use of some interleukin inhibitors may be safer than methotrexate, other older systemic medications, anti-tumor necrosis factor biologics, and tofacitinib for serious infection risk in older adults ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share.